Ann: FIRST MILESTONE ON PATH TO CDH17 CAR T CLINICAL TRIAL, page-4

ASX Announcement October 22, 2021

CHIMERIC ACHIEVES FIRST MILESTONE ON THE PATH TO
CDH17 CAR T CLINICAL TRIAL

• Phase 1 plasmid manufacturing commenced
• Phase 1 clinical trial for neuroendocrine & colorectal tumors planned for 2022
• Positions Chimeric to have a minimum of two Phase 1 trials underway during 2022

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and the
ASX leader in cell therapy, is pleased to announce the successful completion of manufacturing
for CHM 2101 research grade plasmids, a critical first step in the development of CDH17 CAR T.
Manufacturing of CAR T therapies is dependent upon plasmids and viral vectors that hold the
genetic instructions for each specific CAR T product. Plasmids are small DNA molecules that
carry genetic instructions and their successful manufacture marks an important early step for
all CAR T therapies.

In collaboration with the University of Pennsylvania, all of the research grade helper and
transfer plasmids for the CDH17 CAR T have been completed and released. The achievement of
this first step in CAR T manufacturing enables progression to research vector manufacturing,
GMP plasmid and vector manufacturing and advancement of technical operations in readiness
for the CDH17 CAR T phase 1 clinical trial.

Chimeric’s CEO and Managing Director Jennifer Chow said: “We are very pleased that we have
been able to achieve this key first step so rapidly after licensing. This accomplishment speaks to
the commitment and drive that the Chimeric and University of Pennsylvania teams share to
move this important CAR T forward to Phase 1 clinical trials.”

In addition to commencing the CDH17 CAR T Phase 1 trial in 2022, Chimeric is also progressing
its CLTX CAR T Phase 1 clinical trial in glioblastoma (brain cancer) at The City of Hope Cancer
Centre in California, where patients are now receiving second dose levels.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper